Dyslipidemia Drugs Market Capacity, Production,
Revenue, Price and Gross Margin 2018-2025
Dyslipidemia is a chronic metabolic syndrome that refers to an abnormal level
of blood lipids wherein there may be either lipoprotein overproduction or
deficiency. Dyslipidemia can affect any lipid parameter such as HDL cholesterol
levels, LDL cholesterol levels, triglycerides, or a combination of these lipids.
11 th October 2018 - Global Dyslipidemia Drugs Market is expected to grow at a significant CAGR in
the upcoming years as the scope and its applications are increasing across the globe. Dyslipidemia is
a chronic metabolic syndrome that refers to an abnormal level of blood lipids wherein there may be
either lipoprotein overproduction or deficiency.
Dyslipidemia can affect any lipid parameter such as HDL cholesterol levels, LDL cholesterol levels,
triglycerides, or a combination of these lipids. There are numerous causes of Dyslipidemia such as
mutated genes, diabetes, poor or high fat, liver diseases, alcohol abuse, cigarette smoking, etc.
There are various types of drugs available in the market to treat Dyslipidemia namely Bile Acid
Resins, Niacins, Statins, etc. The treatment of Dyslipidemia also include exercise, reduced saturated
fats in the diet, etc.
Browse Full Research Report @
https://www.millioninsights.com/industry-reports/dyslipidemia-drugs-market